A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
Astellas Pharma Inc
A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent
OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who
received at least 1 but no more than 2 prior drug regimens
OSI-906 and Irinotecan in Patients With Advanced Cancer
University of Colorado, Denver
This study plans to learn more about an investigational drug called OSI-906. OSI-906 is
being looked at to see if it could be a treatment for advanced cancer. "The FDA is the U.S.
government agency that reviews the results of research of drugs and decides if it can be
sold in the U.S. OSI-906 has been given to over 185 people with cancer.
Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
National Cancer Institute (NCI)
Phase 1/Phase 2
This phase I/II trial studies the side effects and best dose of linsitinib when given
together with erlotinib hydrochloride and radiation therapy after surgery in treating
patients with advanced or recurrent head and neck cancer. Erlotinib hydrochloride and
linsitinib may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation
therapy together with erlotinib hydrochloride and linsitinib may kill more tumor cells.
Giving these treatments after surgery may kill any tumor cells that remain after surgery.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.